Tempus Expands Multi-Year Deal With Moderna and Merck

$TEM has expanded its multi-year relationship with $MRNA and $MRK to support the potential commercialization of intismeran autogene.
Tempus will provide sequencing and sample logistics tied to individual patients, embedding its infrastructure more deeply into the treatment workflow.
The expanded agreement moves Tempus further into therapy development and commercialization, with testing and logistics potentially becoming recurring components of each patient's treatment process.